Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.35 |
| ▸ | CPB1 | P15086 | 1/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.30 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.30 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL971547 | 1.00 | CPB2 (0.35) | CPB2CPB1HCAR3ITGB1ITGA4 | |
| SCHEMBL10915791 | 0.87 | CPB2 (0.36) | CPB2CPB1 | |
| SCHEMBL31254181 | 0.85 | SIRT2 (0.33) | — | |
| SCHEMBL5893971 | 0.83 | CPB2 (0.32) | CPB2CPB1 | |
| SCHEMBL5893967 | 0.83 | CPB2 (0.32) | CPB2CPB1 | |
| SCHEMBL147911 | 0.82 | CPB2 (0.38) | CPB2CPB1 | |
| SCHEMBL28558505 | 0.82 | CPB2 (0.38) | CPB2CPB1 | |
| SCHEMBL10777853 | 0.82 | CPB2 (0.40) | CPB2CPB1 | |
| SCHEMBL7074055 | 0.82 | CPB2 (0.40) | CPB2CPB1 | |
| Hydrochloric Acid SCHEMBL31172342 | 0.82 | CPB2 (0.31) | CPB2CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106573895-A | Novel 5-acylsulfanyl-histidine compounds as precursors for the corresponding 5-sulfanylhistidines and disulfides thereof | 特瑞海德公司 | 2017-04-19 | — | — | CN | claimed |
| CN-1133173-A | Preparation of diuretic by using neuropsychic tension antagonist | SANOFI SA (FR) | 1996-10-16 | — | — | CN | claimed |
| CN-119823223-A | Apelin peptide energy macrocycle and application thereof | SOCPRA健康与人文科学有限公司 | 2025-04-15 | — | — | CN | disclosed |
| EP-4448547-A1 | APELINERGIC MACROCYCLES AND USES THEREOF | Socpra Sciences Santé Et Humaines S.E.C. (CA) | 2024-10-23 | — | — | EP | disclosed |
| CN-118829646-A | Apelin peptide energy macrocycle and application thereof | SOCPRA健康与人文科学有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20240343761-A1 | APELINERGIC MACROCYCLES AND USES THEREOF | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2024-10-17 | — | — | US | disclosed |
| WO-2024151890-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-06-27 | — | — | US | disclosed |
| US-20240207418-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. | 2024-06-27 | — | — | US | disclosed |
| CN-118055943-A | Cyclic peptide antibiotics | 基因泰克公司 | 2024-05-17 | — | — | CN | disclosed |
| EP-4366777-A2 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-2265283-A1 | AURISTATIN DRUG LINKER CONJUGATES | Seattle Genetics, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009117531-A1 | AURISTATIN DRUG LINKER CONJUGATES | SEATTLE GENETICS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20080081801-A1 | PORPHYRIN OXYGEN INFUSION FOR INCREASING CONCENTRATIONS IN TUMOR TISSUES | TSUCHIDA EISHUN | 2008-04-03 | — | — | US | disclosed |
| US-20050222116-A1 | Porphyrin oxygen infusion preparation for increasing oxygen concentration in tumor tissue | NIPRO CORPORATION (JP) | 2005-10-06 | — | — | US | disclosed |
| CN-1674891-A | Porphyrin oxygen infusion preparation for increasing oxygen concentration in tumor tissue | NIPRO CORP (JP) | 2005-09-28 | — | — | CN | disclosed |
| EP-1512399-A1 | PORPHYRIN OXYGEN INFUSION PREPARATION FOR INCREASING OXYGEN CONCENTRATION IN TUMOR TISSUE | Nipro Corporation (JP) | 2005-03-09 | — | — | EP | disclosed |
| CN-1133173-A | Preparation of diuretic by using neuropsychic tension antagonist | SANOFI SA (FR) | 1996-10-16 | — | — | CN | disclosed |
| WO-1990006914-A1 | N-ALKYLATION OF N-ALPHA-BOC-PROTECTED AMINO ACIDS | THE UPJOHN COMPANY (US) | 1990-06-28 | — | — | WO | disclosed |
| US-4880781-A | HYPOTENSIVE AGENTS | THE UPJOHN COMPANY (US) | 1989-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207418-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | CPB2 2555/4885CPB1 2381/4885HCAR3 153/4885 |
| US-20240343761-A1 | APELINERGIC MACROCYCLES AND USES THEREOF | APLNR, AP3D1, AP3B1 | CPB2 440/4885CPB1 904/4885HCAR3 201/4885 |
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | CPB2 2555/4885CPB1 2381/4885HCAR3 153/4885 |
| US-20080081801-A1 | PORPHYRIN OXYGEN INFUSION FOR INCREASING CONCENTRATIONS IN TUMOR TISSUES | ALB, PPOX, PPIF | CPB2 568/4885CPB1 768/4885HCAR3 4306/4885 |
| US-20050222116-A1 | Porphyrin oxygen infusion preparation for increasing oxygen concentration in tumor tissue | ALB, PPOX, PPIF | CPB2 734/4885CPB1 935/4885HCAR3 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.